In a time of Covid-shaming, it’s difficult to publicly embrace a rising market that ignores increasing deaths, unfathomable unemployment, massive business failures, a possible 40% to 50% drop in economic activity this quarter and huge federal deficits. Read the full article on CNBC.com
I think that acts of charity, compassion, and creative generosity may resonate with investors increasingly drawn to socially responsible investing when the pandemic comes to an end. Read the full article on CNBC.com
Karen Firestone offers her thoughts on the bailout being offered to the travel and leisure industry. In comparing the bailout to the Great Recession in 2008/2009, she thinks this one should come with strings attached. Read the full article on CNBC.com
Kari was quoted in an article for Penta about gender diversity on corporate boards, originally published on 2/18/20. In January, Goldman Sachs made headlines when it became the first Wall Street investment bank to draw a line on board diversity, with CEO David Solomon declaring that his firm wouldn’t take companies public in the U.S. or Europe…
Millions of people have a stake in corporate America through mutual funds. But you may be surprised by how those funds are voting on your behalf. Read the full article in The New York Times
When the U.S. Business Roundtable announced that it was redefining the purpose of a corporation to accommodate a broader group of stakeholders – extending beyond shareholders to include employees, customers, suppliers and communities – the stock market didn’t seem to react. I saw no thick reports from market strategists detailing how these new principles would affect company…
Come on, Amazon, do we really need another headache? I’m not talking about you missing third quarter earnings last week. I’m talking about the article in the Wall Street capitalist-defending-Journal (not the New Yorker). Read my full article on CNBC.com
In many spheres, such as politics, media and entertainment, women have made considerable progress in reaching executive leadership positions, achieving higher pay, and building new enterprises. But this ascent hasn’t been achieved everywhere. In my own industry, investing, progress has been painfully slow. Read the full article in The Harvard Business Review
This article was originally posted by CNBC.com Kari Firestone’s newest article discusses why the incentives for companies and research organizations may not be aligned with customers’ desire for lower drug prices. Additionally, the legal complexity of the Medicare system leaves the government with no negotiating power, further inflating prescription drug prices. Read the full article…
It’s time for courts to weigh in on the issue of drug pricing. As an investor, we want drug companies to earn a strong return on their investment – but using the “value of a life” thesis to justify price is too arbitrary as that might be infinite. Read the full article in The New…